Stephen G. Machatha, Ph.D.

Stephen G. Machatha, Ph.D.

Chief Development OfficeratAldeyra Therapeutics· In proxies 2022–2025

Pay in FY2025Aldeyra Therapeutics stock +3.8% the same year

Stephen G. Machatha, Ph.D. was paid $1.5M in FY2025 (Dec). Aldeyra Therapeutics stock rose 3.8% that year.

Pay$100 in the stock at the end of FY21 → $91
Pay is from the Summary Compensation Table of each Aldeyra Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Aldeyra TherapeuticsPublic company · 4 yr
    • Chief Development Officer2022 – Present · 4 yrStock in role -83%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?